Hypercalcemia associated with a tongue cancer that manifested a significant response to serum calcium-lowering action of synthetic eel calcitonin. Report of a case.

概要

論文の詳細を見る
Oral tumors are occassionally associated with hypercalcemia. Systemic symptoms due to hypercalcemia cause not only physical and mental troubles to patients but difficulties to physicians in choice of therapy and in prediction of prognosis since these symptoms resemble those seen at terminal stage of cancer. In the treatment of malignant hypercalcemia, simple, safe and efficient therapy that even cachectic cancer patients are able to toleate should be promptly performed.<BR>In the case reported here, a patient with tongue cancer diagnosed histologically squamous cell carcinoma, who manifested prominent hypercalcemia at a terminal stage of his clinical course was treated with synthetic eel calcitonin (Elcitonin). Administration of drug at a dosage of 160 MRCU/day intramusculary resulted in a significant decrease in serum calcium levels without notable side effects. Coadministration of glucocorticoid (Solu-Medral 250 mg/day) enhanced the effect of calcitonin.<BR>We, therefore, suggest that calcitonin with its known inhibitory action on bone resorption is one of the safest and most efficacious drugs for the treatment of hypercalcemia associated with oral cancers.
社団法人日本口腔外科学会の論文